Literature DB >> 23900322

[Burden among caregivers of patients with Parkinson disease].

Olga Benavides1, Daniela Alburquerque, Pedro Chaná-Cuevas.   

Abstract

BACKGROUND: Parkinson disease (EPI) patients often require being assisted by others. These caregivers are exposed to a decrease in their quality of Ufe. AIM: To explore Parkinson disease patient features associated with a greater burden among their caregivers.
MATERIAL AND METHODS: Fifty one patients with Parkinson disease (aged 67 ± 12 years, 29 men, with 8 ± 5 years of disease) and their caregivers, were studied. Patients were assessed with the Unified Parkinson Disease Rating Scale III, the Hoehn & Yahr stage standardization, Parkinson s minimental test, the neuropsychiatric inventory and the Beck Depression Inventory (IDB). The Zarit Burden Interview (ESZ) was applied to caregivers.
RESULTS: According to IDB, 45% of patients whose caregivers presented little or no burden had a depression, compared to 78% of those whose caregivers had modérate or intense burden. (p < 0.01). The ESZ score of caregivers correlated significantly with Parkinson patients' age, IDB and axial involvement in the UPDRS-III (correlation coefficients ofOAp < 0.01, 0.6p < 0.01 and 0.46 p < 0.01, respectively).
CONCLUSIONS: Motor alterations, cognitive impairment and most importantly depression of patients with Parkinson disease are deteminants of burden for their caregivers.

Entities:  

Mesh:

Year:  2013        PMID: 23900322     DOI: 10.4067/S0034-98872013000300006

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  1 in total

1.  Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden.

Authors:  Nicola Modugno; Angelo Antonini; Alessandro Tessitore; Pietro Marano; Francesco Ernesto Pontieri; Nicola Tambasco; Margherita Canesi; Giovanni Fabbrini; Mariachiara Sensi; Rocco Quatrale; Paolo Solla; Giovanni Defazio; Gabriella Melzi; Giuliana Gualberti; Leonardo Lopiano
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-02       Impact factor: 2.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.